Gene Therapy Innovation From Platform To Process

Significant challenges persist in enhancing AAV production within insect and mammalian cells, as these systems were not naturally evolved to function as efficient AAV factories. These limitations create bottlenecks in yield, scalability, and consistency, posing obstacles for gene therapy developers.

Ascend is tackling these barriers head-on by applying cutting-edge engineering solutions designed to optimize cellular machinery and streamline production processes. Through advancements in host cell engineering, vector design, and bioprocess optimization, our goal is to achieve a groundbreaking 100-fold improvement in AAV yield over the next decade, setting new industry standards for efficiency and scalability.